# Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)

> **NCT01963260** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 50 (actual)

## Conditions studied

- Immune Thrombocytopenia Purpura

## Interventions

- **DRUG:** MK-8723
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT01963260
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-31
- **Primary completion:** 2015-04-26
- **Final completion:** 2015-04-26
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01963260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01963260, "Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01963260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*